Analysis:

## (a) Source Analysis

**Web Articles:**

1. **Verisign Q4 2025 Earnings Call Schedule (Jan 5, 2026)**: Minimal content, confirms Feb 5, 2026 earnings date. Stock down 1.43% at article time. Quality: Low (incomplete extraction).

2. **Nasdaq Earnings Page**: Unusable - extraction failed, only error messages.

3. **Public.com Earnings Dashboard**: Good quality. Q3 2025 actual EPS $2.27 vs estimate $2.24 (beat by 1.34%). Next earnings Feb 5, 2026, projected EPS $2.28. Historical context valuable.

4. **MarketBeat Institutional Holdings (Feb 2, 2026)**: Excellent quality, very recent. **Key facts**: Current price $244.23, 52-week range $211.79-$310.60, 50-day MA $247.26, 200-day MA $260.87, 92.90% institutional ownership. CEO Bidzos sold 5,000 shares Nov 11 at $248.14. **Analyst opinions (identifiable sources)**: Citigroup "Buy", JPMorgan "Neutral" with $271 target (Jan 6), Zacks "Strong Sell" (Dec 30), Robert W. Baird $325 target, consensus "Hold" at $282.

5. **TechStockÂ² Outlook (Nov 30, 2025)**: Excellent detailed analysis. **Key facts**: Last traded $251.99 (Nov 28), YTD +23%, Q3 revenue $387M (+5.7% YoY), net income $213M, EPS $2.12 (+10.4% YoY), operating margin 67.2%. Berkshire sold 4.3M shares July 29 at $285 (reducing to ~9.6%). **Expert opinion**: DCF fair value ~$295-296, consensus targets $275-300 range. Structural issues: .com registry renewal and .web litigation ongoing.

6. **Barchart Earnings Preview (Jan 12, 2026)**: Good quality. **Key facts**: 52-week performance VRSN +17.6% vs S&P 500 +17.7%. Q4 2025 expected EPS $2.29 (+14.5% YoY). Q3 2025: revenue $419.1M (beat $416.8M estimate), EPS $2.27 (beat by 1.3%), stock down >1% post-announcement. **Analyst consensus**: "Moderate Buy", average target $311 (24.9% upside).

**AskNews Articles:**

1. **Varonis Systems (VRNS) lawsuit articles (Feb 2, 2026)**: Wrong ticker - these concern VRNS, not VRSN. Irrelevant.

2. **Verses AI (VRSSF) article (Feb 2, 2026)**: Wrong ticker. Irrelevant.

3. **Goldman Sachs ETF increases VRSN stake (Feb 2, 2026)**: Factual. Increased by 2.39% to 262,727 shares ($66.2M). Stock data: Market cap $22.64B, P/E 28.47, beta 0.21, 50-day MA $247.36, 200-day MA $266.27.

4. **VerifyMe (VRME) Nasdaq compliance (Feb 2, 2026)**: Wrong ticker. Irrelevant.

5. **Strategy Asset Managers invests $654K in VRSN (Feb 2, 2026)**: Factual. New 2,341 share position. Confirms institutional activity. Stock opened $244.23 on Feb 2.

6. **Multiple institutional activity articles (Feb 1-2, 2026)**: Mediolanum reduced stake 16.1%, Krilogy reduced 19.95%, Mirae increased 9.6%, Bank of NY Mellon reduced 3.7%. **Consistent fact**: 92.90% institutional ownership, stock at $244.23.

7. **VRSN shares up 2.81% Jan 21 (Jan 21, 2026)**: Stock closed $255.08, up from $248.11. **Analyst forecast**: Average 1-year target $299.51 (17.42% upside), GF Value $275.25 (7.91% upside).

8. **Barchart Earnings Preview duplicate**: Same content as web article #6.

9. **Historical insider selling articles (Oct-Dec 2025)**: CEO Bidzos sold multiple times: Dec 9 ($244.59), Nov 11-19 ($242.07-$248.14), Oct 14-22 ($261.54-$288.48). Pattern of consistent insider selling.

10. **Q3 2025 earnings reaction (Oct 25, 2025)**: Stock fell 7.5% to $231.86 after earnings, despite beating estimates ($2.27 vs $2.25). Previous close $250.58. **Critical insight**: Even with beat, stock declined.

**Key Identifiable Expert Opinions:**
- Citigroup: Buy
- JPMorgan: Neutral, $271 target (most recent, Jan 6, 2026)
- Zacks: Strong Sell (Dec 30, 2025)
- Robert W. Baird: $325 target
- Consensus: Hold, $282 average target

## (b) Evidence Analysis

**Strong Evidence:**

1. **Earnings catalyst on Feb 5, 2026** (multiple independent sources confirm): Directly impacts the Feb 3-11 window. Historical pattern: Q3-25 (-1.3% despite beat), Q2-25 (+6.5%), Q1-25 (+9.3%). Most recent reaction was negative despite beat - this is highly relevant structural evidence.

2. **Current technical position** (multiple sources, Feb 1-2 data): Stock at $244.23, below 50-day MA ($247.26) and significantly below 200-day MA ($260.87). This represents confirmed weakness entering the period. Stock was $255.08 on Jan 21, meaning 4.3% decline in ~10 days leading to Feb 3.

3. **Consistent insider selling** (SEC filings, multiple dates): CEO sold shares in Oct, Nov, Dec, Jan at prices ranging $242-$288. No offsetting purchases. While potentially scheduled (10b5-1), pattern suggests insiders not accumulating.

**Moderate Evidence:**

1. **Q3 2025 earnings reaction precedent** (Oct 25, 2025): Stock fell 7.5% day after earnings despite beating estimates. This is the most recent comparable event and directly relevant, though single data point.

2. **Analyst consensus shift** (Dec 30, 2025 - Jan 6, 2026): Zacks downgrade to Strong Sell (Dec 30) vs JPMorgan maintaining Neutral with modest $271 target (Jan 6). Mixed signals but recent negative sentiment from identifiable source.

3. **52-week positioning** (current data): At $244.23, stock is 21.3% below 52-week high ($310.60) but 15.3% above 52-week low ($211.79). Suggests mid-range positioning, not at extremes.

**Weak Evidence:**

1. **Institutional buying/selling activity** (Q3 2025 data, reported Feb 2026): Mixed - some increased, some decreased. Net 92.90% institutional ownership stable. This is backward-looking Q3 data reported with lag.

2. **YTD performance comparison** (various dates): VRSN +17.6% vs S&P 500 +17.7% over 52 weeks (from Barchart article dated Jan 12). Slightly underperforming but marginal difference.

## (c) Timeframe Analysis

**Prediction Timeframe:** 6 trading days (Feb 3 close to Feb 11 close)

**Critical Timeline:**
- Feb 3 (Monday): Starting price
- Feb 5 (Wednesday): Q4 2025 earnings after market close
- Feb 6 (Thursday): First full trading day post-earnings
- Feb 11 (Tuesday): Ending price

**If timeframe halved (3 trading days, Feb 3-6):**
Probability would increase to ~60-62%. Shorter window means less time for negative drift or reversal. If earnings beat expectations, initial positive reaction on Feb 6 would dominate the outcome. Less time for profit-taking or secondary factors.

**If timeframe doubled (12 trading days, Feb 3-21):**
Probability would decrease to ~48-50%. Longer window introduces more variables: broader market movements, follow-on analyst reactions, potential .web litigation news, general mean reversion. The earnings catalyst becomes diluted over time.

**Key consideration:** The 4-day post-earnings buffer (Feb 6-11) allows initial reactions to stabilize but also permits reversal if results disappoint or market finds concerns in guidance.

## (d) Justification

**Outside View Base Rate:** 55% (from previous analysis: 67% recent earnings positive reactions, adjusted down for current weakness and Q3-25 negative precedent)

**Factors Supporting Higher Price (Yes outcome):**

1. **Potential earnings beat**: Company has beaten estimates recently (Q3: $2.27 vs $2.24, Q2: $2.21 vs $2.20). Consensus $2.28 for Q4 may be beatable.

2. **Oversold positioning**: Stock at $244.23 is 21% below 52-week high and below both moving averages. Technical bounce possible if results solid.

3. **Time for absorption**: 4 trading days post-earnings allows positive news to be fully digested.

4. **Fundamental strength**: 67.2% operating margin, consistent revenue growth (+5.7% Q3 YoY), strong cash generation.

**Factors Supporting Lower Price (No outcome):**

1. **Q3-25 precedent is damning**: Most recent earnings (Oct 23) showed beat on both revenue and EPS, yet stock fell 7.5% next day and continued declining. This suggests market is looking for more than just beats - perhaps acceleration or new catalysts.

2. **Recent momentum negative**: Stock down from $255.08 (Jan 21) to $244.23 (Feb 1), a 4.3% decline in ~10 days. This weakness leading into earnings often continues.

3. **No obvious new catalyst**: Dividend already established, buyback ongoing. Unless guidance is raised significantly, inline results may not excite.

4. **Insider selling pattern**: CEO consistently selling since August 2025, including recent sales at $248 level (Nov). No insider buying signals confidence.

5. **Analyst skepticism**: Zacks Strong Sell (Dec 30), JPMorgan only $271 target (10.9% upside), consensus Hold. No strong buy recommendations recently.

6. **Mature business concerns**: Domain registry growth limited. Market may be pricing in plateau.

**Critical Adjustment from Outside View:**

The Q3-25 earnings reaction is the most important piece of evidence. The stock fell 7.5% despite beating estimates. This happened just 3.5 months ago and represents the market's most recent judgment on VRSN earnings quality. 

**Key insight**: The market is no longer rewarding VRSN for simply meeting/beating estimates. It wants growth acceleration or new catalysts. Without evidence that Q4 will provide this (and no such evidence exists in the sources), we should weight the Q3-25 negative reaction heavily.

**Adjustment logic:**
- Start: 55% (outside view)
- Q3-25 precedent (strong evidence, negative): -8%
- Recent price weakness into earnings (strong evidence, negative): -5%
- Insider selling pattern (moderate evidence, negative): -3%
- Technical oversold potential (moderate evidence, positive): +4%
- Time buffer for positive absorption (weak-moderate evidence, positive): +2%

**Adjusted probability: 55% - 8% - 5% - 3% + 4% + 2% = 45%**

## Probability Calibration

Starting from the outside view of 55%, I must heavily weight the Q3-25 earnings precedent where the stock fell 7.5% despite beating estimates. This is the most directly analogous event and occurred recently enough to reflect current market sentiment toward VRSN.

The current technical setup (below both MAs, recent 4.3% decline) reinforces negative momentum. While the stock could bounce if results are strong, the pattern suggests the market is demanding more than just beats.

At 45%, I'm saying that in 45 out of 100 similar scenarios, the stock would be higher on Feb 11 than Feb 3. This is slightly below coin-flip odds, reflecting:
- The earnings catalyst creates opportunity for movement in either direction
- Recent precedent favors downside even on beats
- Current weakness suggests continued pressure
- But fundamental quality and potential for positive surprise prevents going below 40%

**Consistency check**: "45 out of 100 times, VRSN closes higher on Feb 11 than Feb 3" means I expect it to be lower slightly more often than higher. This aligns with the negative Q3 precedent and current weakness while acknowledging meaningful uncertainty around the earnings catalyst.

## Checklist:

1. **Paraphrase**: Will VRSN stock price on Feb 11, 2026 close be higher than Feb 3, 2026 close? 6 trading days, earnings Feb 5.

2. **Base rate**: Outside view 55% (from recent earnings reactions adjusted for weakness). Final 45% represents significant adjustment based on Q3-25 precedent.

3. **Consistency**: "45 out of 100 times, VRSN closes higher on Feb 11 than Feb 3." This reflects slightly bearish lean due to Q3 precedent and current weakness, while acknowledging earnings uncertainty.

4. **Key evidence**:
   - Q3-25: Stock fell 7.5% despite earnings beat (Oct 25) - verified from multiple sources
   - Current price $244.23 below 50-day MA $247.26 and 200-day MA $260.87 (Feb 1-2) - verified
   - Recent decline: $255.08 (Jan 21) to $244.23 (Feb 1), down 4.3% - verified
   - CEO insider selling: Multiple sales Oct-Jan, no purchases - verified from SEC filings
   - Earnings Feb 5: Consensus $2.28 EPS - verified from multiple sources

5. **Blind spot**: If Q4 results significantly beat expectations AND include positive surprise (major guidance raise, new strategic initiative, resolution of .web litigation favorably), the stock could rally 5-10%+ and my forecast would look overly pessimistic. However, no evidence suggests such surprises are likely.

6. **Status quo**: Stock has been declining into earnings (down 4.3% since Jan 21). Status quo continuation would suggest further weakness or flat performance, supporting sub-50% probability.

Probability: 45%